Invention Grant
- Patent Title: Method of treating cancer with an anti-CCR8 having antibody-dependent cell-mediated cytotoxicity (ADCC) activity against cells expressing CCR8
-
Application No.: US16183216Application Date: 2018-11-07
-
Publication No.: US10550191B2Publication Date: 2020-02-04
- Inventor: Tetsuya Yoshida , Yujiro Kidani , Mitsunobu Matsumoto , Takayuki Kanazawa , Satomi Shinonome , Kanji Hojo , Naganari Ohkura , Shimon Sakaguchi , Atsushi Tanaka , Hisashi Wada , Atsunari Kawashima , Norio Nonomura
- Applicant: SHIONOGI & CO., LTD. , OSAKA UNIVERSITY
- Applicant Address: JP Osaka-shi, Osaka JP Suita-shi, Osaka
- Assignee: Shionogi & Co., Ltd.,Osaka University
- Current Assignee: Shionogi & Co., Ltd.,Osaka University
- Current Assignee Address: JP Osaka-shi, Osaka JP Suita-shi, Osaka
- Agency: Morgan, Lewis & Bockius LLP
- Priority: JP2017-065603 20170329; JP2017-185935 20170927
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61P35/00 ; A61K39/00
Abstract:
The present invention provides a pharmaceutical composition for cancer treatment comprising an antibody against CCR8.
Public/Granted literature
- US20190071508A1 PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT Public/Granted day:2019-03-07
Information query
